Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study

Abstract

Background:

Mendelian randomization (MR) studies have demonstrated strong support for an association between genetically increased body mass index and risk of multiple sclerosis (MS). The adipokine adiponectin may be a potential mechanism linking body mass to risk of MS.

Objective:

To evaluate whether genetically increased adiponectin levels influence risk of MS.

Methods:

Using genome-wide significant single nucleotide polymorphisms (SNPs) for adiponectin, we undertook an MR study to estimate the effect of adiponectin on MS. This method prevents bias due to reverse causation and minimizes bias due to confounding. Sensitivity analyses were performed to evaluate the assumptions of MR.

Results:

MR analyses did not support a role for genetically elevated adiponectin in risk of MS (odds ratio (OR) = 0.93 per unit increase in natural-log-transformed adiponectin, equivalent to a two-standard deviation increase in adiponectin on the absolute scale; 95% confidence interval (CI) = 0.66–1.33; p = 0.61). Further MR analysis suggested that genetic variation at the adiponectin gene, which influences adiponectin level, does not impact MS risk. Sensitivity analyses, including MR-Egger regression, suggested no bias due to pleiotropy.

Conclusion:

Lifelong genetically increased adiponectin levels in humans have no clear effect on risk of MS. Other biological factors driving the association between body mass and MS should be investigated.

Keywords

Multiple sclerosis adiponectin Mendelian randomization analysis genetic epidemiology

Get full access to this article

View all access options for this article.

References

Friese

Schattling

Fugger

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014; 10(4): 225–238, http://www.ncbi.nlm.nih.gov/pubmed/24638138

Versini

Jeandel

P-Y

Rosenthal

et al . Obesity in autoimmune diseases: Not a passive bystander. Autoimmun Rev 2014; 13(9): 981–1000, http://www.sciencedirect.com/science/article/pii/S1568997214001414 (accessed 7 December 2015).

Noseworthy

Lucchinetti

Rodriguez

et al . Multiple sclerosis. N Engl J Med 2000; 343(13): 938–952, http://www.ncbi.nlm.nih.gov/pubmed/11006371

Compston

Coles

Multiple sclerosis. Lancet 2008; 372(9648): 1502–1517, http://www.sciencedirect.com/science/article/pii/S0140673608616207 (accessed 11 July 2015).

Munger

Bentzen

Laursen

et al . Childhood body mass index and multiple sclerosis risk: A long-term cohort study. Mult Scler 2013; 19(10): 1323–1329, http://msj.sagepub.com.proxy3.library.mcgill.ca/content/19/10/1323.long (accessed 24 November 2015).

Munger

Chitnis

Ascherio

Body size and risk of MS in two cohorts of US women. Neurology 2009; 73(19): 1543–1550, http://www.ncbi.nlm.nih.gov/pubmed/19901245

Hedström

Olsson

Alfredsson

High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18(9): 1334–1336, http://www.ncbi.nlm.nih.gov/pubmed/22328681

Langer-Gould

Brara

Beaber

et al . Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80(6): 548–552, http://www.ncbi.nlm.nih.gov/pubmed/24101749

Mokry

Ross

Timpson

et al . Obesity and multiple sclerosis: A Mendelian randomization study. PLoS Med 2016; 13(6): e1002053, http://www.ncbi.nlm.nih.gov/pubmed/27351487

10.

Tilg

Moschen

AR.

Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6(10): 772–783, http://www.nature.com.proxy3.library.mcgill.ca/nri/journal/v6/n10/full/nri1937.html (accessed 2 March 2015).

11.

Esposito

Pontillo

Di Palo

et al . Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. J Am Med Assoc 2003; 289(14): 1799–1804, http://www.ncbi.nlm.nih.gov/pubmed/12684358

12.

Arita

Kihara

Ouchi

et al . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1): 79–83, http://www.sciencedirect.com/science/article/pii/S0006291X99902553 (accessed 31 October 2015).

13.

Piccio

Cantoni

Henderson

et al . Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. Eur J Immunol 2013; 43(8): 2089–2100, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901539/ (accessed 7 December 2015).

14.

Piccio

Stark

Cross

AH.

Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol 2008; 84(4): 940–948.

15.

Kraszula

Jasińska

Eusebio

M-O

et al . Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol 2012; 46(1): 22–28, http://www.sciencedirect.com/science/article/pii/S0028384314600918 (accessed 7 December 2015).

16.

Hietaharju

Kuusisto

Nieminen

et al . Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: A Finnish co-twin study. Eur J Neurol 2010; 17(2): 332–334, http://www.ncbi.nlm.nih.gov/pubmed/19538214 (accessed 7 December 2015).

17.

Palavra

Marado

Mascarenhas-Melo

et al . New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging. Dis Markers 2013; 34(5): 341–348, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809749/ (accessed 8 December 2015).

18.

Penesova

Vlcek

Imrich

et al . Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis 2015; 30(4): 895–901, http://www.ncbi.nlm.nih.gov/pubmed/25809135 (accessed 8 December 2015).

19.

Mokry

Ahmad

Forgetta

et al . Mendelian randomisation applied to drug development in cardiovascular disease: A review. J Med Genet 2015; 52(2): 71–79, http://jmg.bmj.com/content/52/2/71.full.pdf (accessed 22 September 2016).

20.

Lawlor

Harbord

Sterne

JAC

et al . Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27(8): 1133–1163, http://www.ncbi.nlm.nih.gov/pubmed/17886233 (accessed 12 May 2015).

21.

Dastani

Hivert

M-F

Timpson

et al . Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet 2012; 8(3): e1002607, http://dx.plos.org/10.1371/journal.pgen.1002607 (accessed 12 May 2015).

22.

Beecham

Patsopoulos

Xifara

et al . Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45(11): 1353–1360, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832895/

23.

Sawcer

Hellenthal

Pirinen

et al . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476(7359): 214–219, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182531/ (accessed 11 August 2015).

24.

Mokry

Ross

Ahmad

et al . Vitamin D and risk of multiple sclerosis: A Mendelian randomization study. PLoS Med 2015; 12(8): e1001866, http://dx.plos.org/10.1371/journal.pmed.1001866 (accessed 26 August 2015).

25.

Walter

Min

Huang

et al . The UK10K project identifies rare variants in health and disease. Nature 2015; 526(7571): 82–90, http://www.nature.com/doifinder/10.1038/nature14962 (accessed 27 June 2016).

26.

Purcell

Neale

Todd-Brown

et al . PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81(3): 559–575, http://linkinghub.elsevier.com/retrieve/pii/S0002929707613524 (accessed 22 June 2016).

27.

Bowden

Davey Smith

Burgess

Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44(2): 512–525, http://ije.oxfordjournals.org.proxy3.library.mcgill.ca/content/44/2/512.long (accessed 17 November 2015).

28.

Egger

Davey Smith

Schneider

et al . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629–634, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127453/ (accessed 27 October 2015).

29.

Yaghootkar

Lamina

Scott

et al . Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and Type 2 diabetes. Diabetes 2013; 62(10): 3589–3598, http://diabetes.diabetesjournals.org/cgi/doi/10.2337/db13-0128 (accessed 22 June 2016).

30.

Huckins

Boraska

Franklin

et al . Using ancestry-informative markers to identify fine structure across 15 populations of European origin. Eur J Hum Genet 2014; 22(10): 1190–1200, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169539/ (accessed 16 December 2015).

31.

Burgess

Butterworth

Thompson

SG.

Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37(7): 658–665, http://doi.wiley.com/10.1002/gepi.21758 (accessed 14 December 2015).

32.

R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2015, https://www.r-project.org/

33.

Hug

Wang

Ahmad

et al . T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004; 101(28): 10308–10313, http://www.pnas.org.proxy3.library.mcgill.ca/content/101/28/10308.long (accessed 17 February 2016).

34.

Zhornitsky

McKay

Metz

et al . Cholesterol and markers of cholesterol turnover in multiple sclerosis: Relationship with disease outcomes. Mult Scler Relat Disord 2016; 5: 53–65, http://www.sciencedirect.com/science/article/pii/S2211034815300122 (accessed 20 February 2016).

35.

Natarajan

Hagman

Hämälainen

et al . Adipsin is associated with multiple sclerosis: A follow-up study of Adipokines. Mult Scler Int 2015; 2015: 371734, http://www.hindawi.com/journals/msi/2015/371734/ (accessed 14 December 2015).

36.

Fantuzzi

Adiponectin in inflammatory and immune-mediated diseases. Cytokine 2013; 64(1): 1–10, http://linkinghub.elsevier.com/retrieve/pii/S1043466613005917 (accessed 8 February 2016).

37.

Chen

Assmann

Krenz

et al . Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 2014; 124(5): 2188–2192, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4001545&tool=pmcentrez&rendertype=abstract (accessed 23 February 2016).

38.

Bielekova

Lincoln

McFarland

et al . Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164(2): 1117–1124, http://www.jimmunol.org/content/164/2/1117.full (accessed 4 February 2016).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB